Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment

Neurology

Volumn 73, Issue 24, 2009, Pages 2079-2085

  Tolboom, N ^a,b   Van Der Flier, W M ^c   Yaqub, M ^a   Koene, T ^d   Boellaard, R ^a   Windhorst, A D ^a   Scheltens, P ^c   Lammertsma, A A ^a   Van Berckel, B N M ^a,c  

^a Departments of Nuclear Medicine and PET Research   (Netherlands)

^b Neurology and Alzheimer Centre   (Netherlands)

^c Department of Epidemiology and Biostatistics ^*

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [6 [(2 FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE F 18; CONTRAST MEDIUM; PITTSBURGH COMPOUND B C 11; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HUMAN; ISOTOPE LABELING; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; TEMPORAL CORTEX; TEMPORAL LOBE;

EID: 73349125078     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c679cc     Document Type: Article

References (36)

1. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Backman L. The course of cognitive impairment in preclinical Alzheimer disease: three-and 6-year follow-up of a population-based sample. Arch Neurol 2000;57:839-844.
2. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
3. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
4. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319.
5. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-2663.
6. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598-10606.
7. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4'- methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-2092.
8. Boxer AL, Rabinovici GD, Kepe V, et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology 2007;69:283-290.
9. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001;21:RC189.
10. Tolboom N, Yaqub M, van der Flier WM, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med 2009;50:191-197.
11. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130: 2837-2844.
12. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated /3-amyloid deposition in elderly subjects. Brain 2009;132: 1310-1323.
13. Braskie MN, Klunder AD, Hayashi KM, et al. Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol Aging 2008.
14. Verhage F. Intelligentie en Leeftijd: onderzoek bij Neder-landers van twaalf tot zevenenzeventig jaar [Intelligence and Age: Study with Dutch People Aged 12 to 77]. Assen: Van Gorcum; 1964.
15. Agdeppa ED, Kepe V, Petri A, et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl) (methyl)amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience 2003;117:723-730.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
17. Wechsler D. Wechsler Adult Intelligence Scale, 3rd ed. San Antonio, TX: Psychological Corporation; 1997.
18. Rey A. L'examen Clinique en Psychologie, 2nd ed. Paris: PUF; 1964.
19. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alz-heimer type. J Neurol Neurosurg Psychiatry 2002;73: 126-133.
20. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
21. Osterrieth PA. The test of copying a complex figure: a contribution to the study of perception and memory. Arch Psychol (Geneve) 1944;30:286-356.
22. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997;38:1614-1623.
23. Tolboom N, Yaqub M, Boellaard R, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Imaging 2009;36:1629-1638.
24. Wilson AA, GarciaA, ChestakovaA, Kung HF, Houle SA. Rapid one-step radiosynthesis of the beta-amyloid imaging radiotracer N-methyl-[C-11]2-('4- methylaminophenyl)-6-hydroxybenzothiazole ([C-11]-6-OH-BTA-1). J Labelled Compds Radiopharm 2004;47:679-682.
25. Klok RP, Klein PJ, van Berckel BN, et al. Synthesis of 2-(1,1-dicyanopropen-2-yl)-6-(2-[18F]-fluoroethyl)-methylamino-naphthalene ([18F]FDDNP). Appl Radiat Isot 2008;66:203-207.
26. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187-198.
27. Svarer C, Madsen K, Hasselbalch SG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 2005;24: 969-979.
28. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 2002;22:1440-1452.
29. Yaqub M, Tolboom N, Boellaard R, et al. Simplified parametric methods for [11C]PIB studies. Neuroimage 2008; 42:76-86.
30. Yaqub M, Boellaard R, van Berckel BNM, et al. Evalua-tion of tracer kinetic models for analysis of [ F]FDDNP studies. Mol Imaging Biol 2009;11:322-333.
31. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:1533-1539.
32. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol 1989;77:314-319.
33. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. AmJ Pathol 1989;135:309-319.
34. Villemagne VL, Pike KE, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsycho-logia 2008;46:1688-1697.
35. Tolboom N, van der Flier WM, Yaqub M, et al. Relation-ship of cerebrospinal fluid markers to [ C]PIB and [ F]FDDNP binding. J Nucl Med 2009;50:1464-1470.
36. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-746.